A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery

BACKGROUND: Uterine leiomyosarcomas (U-LMSs) and soft tissue leiomyosarcomas (ST-LMSs) are rare tumours with poor prognosis when locally advanced or metastatic, and with moderate chemosensitivity. In 2015 we reported very encouraging results of the LMS-02 study (NCT02131480) with manageable toxicity...

Descripción completa

Detalles Bibliográficos
Autores principales: Pautier, P., Floquet, A., Chevreau, C., Penel, N., Guillemet, C., Delcambre, C., Cupissol, D., Selle, F., Isambert, N., Piperno-Neumann, S., Saada-Bouzid, E., Bertucci, F., Bompas, E., Alexandre, J., Collard, O., Lebrun-Ly, V., Soulier, P., Toulmonde, M., Le Cesne, A., Lacas, B., Duffaud, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446791/
https://www.ncbi.nlm.nih.gov/pubmed/34325109
http://dx.doi.org/10.1016/j.esmoop.2021.100209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446791/
https://www.ncbi.nlm.nih.gov/pubmed/34325109
http://dx.doi.org/10.1016/j.esmoop.2021.100209

Ejemplares similares